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OBJECTIVE: Oral health can affect a patient’s general health and quality of life. Given the increase in breast cancer
survival rates, investigations of factors influencing the quality of life of survivors have gained importance.
Therefore, the objective of our study was to characterize oral health in postmenopausal breast cancer survivors.
METHODS: We conducted a matched case-control study. Forty-eight women who survived breast cancer (age
62.1¡9.1 years) and 48 healthy controls (age 61.8¡8.6 years) were included. For each case and control, a
complete oral evaluation chart was completed.
RESULTS: The prevalence of chronic periodontal disease was 98% in breast cancer survivors and 87% in controls.
The breast cancer survivors had a median of 16 remaining teeth, whereas controls had a median of 22 remaining
teeth (p= 0.03). The percentage of sites with gingival bleeding was 16.05% (0-100%) in breast cancer survivors
and 0% (0-72%) in controls (p= 0.04).
CONCLUSION: Chronic periodontal disease and tooth loss were highly prevalent in postmenopausal breast cancer
survivors. To improve survivors’ quality of life, a preventive oral health evaluation should be available prior to
cancer treatment.
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& INTRODUCTION
Breast cancer mortality has declined dramatically since
1990 (1). In the U.S., breast cancer death rates have
decreased by 34% (2). This epidemiological change can be
attributed to a combination of screening programs and
improvements in adjuvant therapy (3). In this context, an
important issue faced by clinicians caring for these women
is how to improve their long-term quality of life. Many
latent clinical disorders can emerge during or after cancer
treatment that eventually may attenuate the survival gains
obtained via recent advances in curative-intent therapies (4).
Good oral health is important to quality of life and overall
health. Chronic periodontal disease (CPD) is associated with
low flow-mediated dilation of the brachial artery and high
levels of systemic inflammation markers (5). CPD is also
associated with atherogenesis (6) and a risk of myocardial
infarction and stroke (7). Oral care during cancer treatment
primarily focuses on the management of acute complica-
tions, such as mucositis, oral pain and infection (8). Chronic
oral diseases have the potential to impair survivors’ quality
of life after oncological treatment and are frequently
neglected.
In this study, we report the results of a systematic oral
evaluation after breast cancer treatment in postmenopausal
women. Our objective was to characterize the oral health in
breast cancer survivors treated in the public health system.
& MATERIALS AND METHODS
Subjects
This case-control study included 48 voluntary post-
menopausal breast cancer survivors and 48 age-matched
healthy women volunteers. The cases and matched controls
were recruited from the public health system in Brazil.
Oral examination
The oral examinations were conducted by a single
calibrated dental examiner who collected the complete
clinical history of the patients and performed the clinical
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oral examination. The oral examinations were performed
after the end of oncological treatment for all breast cancer
survivors. The data included the following: the total number
of teeth, full-mouth plaque score (the number of sites with
detectable dental plaque divided by the total number of
sites per mouth, multiplied by 100), full-mouth gingival
bleeding on probing score (the number of sites with gingival
bleeding on probing divided by the total number of sites per
mouth, multiplied by 100), full-mouth periodontal lesion
score (the number of sites with a probing depth $4 mm
divided by the total number of sites per mouth, multiplied
by 100) and the mean probing attachment level.
Statistics
The data for each variable were tested using the
D’ Agostino & Pearson normality test. The mean and
standard deviation or median and range were determined.
Student’s t test or the Mann-Whitney test was performed as
appropriate. All analyses were performed using GraphPad
SoftwareH 5.0 for Windows (GraphPad Software Inc, La
Jolla, CA, USA).
Ethics
The study was approved by the local institutional review
board, and all subjects signed a written informed consent
form. All procedures were in accordance with the Helsinki
Declaration.
& RESULTS
The medical parameters associated with breast cancer are
presented in Table 1. The mean age was 62.1¡9.1 years for
breast cancer survivors and 61.8¡8.6 years for controls.
Oral health data are presented in Table 2. CPD was
identified in 98% of breast cancer survivors (mild period-
ontitis: 30 cases; moderate periodontitis: 11 cases; severe
periodontitis: 6 cases) and 87% of controls (mild period-
ontitis: 23 cases; moderate periodontitis: 12 cases; severe
periodontitis: 7 cases).
The median number of teeth was 16 (3-28) for breast
cancer survivors and 22 (4-31) for controls (p=0.03, Mann-
Whitney test). The median full-mouth plaque score was 50
(0-100) for cancer survivors and 36.57 (0-100) for controls
(p=NS, Mann-Whitney test). The median full-mouth gingi-
val bleeding on probing score was 16.05 (0-100) for the cases
and 0 (0-72) for the controls (p= 0.04, Mann-Whitney test).
The median full-mouth periodontal lesion score was 3.3
(0.0-46.7) for breast cancer survivors and 3.6 (0.0-51.6) for
controls. The probing attachment level was 2.8 (1.3-5.9) in
breast cancer survivors and 3.1 (1.5-5.2) in controls (p=NS,
Mann-Whitney test).
& DISCUSSION
We identified a very high prevalence of CPD in post-
menopausal breast cancer survivors; only one of our
patients did not exhibit signs of the disease. The controls
also presented a high prevalence of CPD; however, breast
cancer survivors had significantly higher indices of gingival
bleeding and tooth loss. These findings are highly relevant
for the multidisciplinary management of breast cancer.
The quality of life and long-term survival of breast cancer
survivors may be affected by lack of oral health care. CPD is
associated with several unpleasant symptoms that can
range from mild to severe, including swelling, bluish purple
discoloration of the gingiva, bleeding after eating or brushing
and halitosis. CPD can also induce loss of supportive con-
nective tissues, including alveolar bone, thereby resulting
in loss of attachment of the periodontal ligament to the
cementum and eventual tooth loss (mainly among older
individuals) (9).
The prevalence of CPD increased significantly with age
and remained constant after the 50–59 age group (10). The
prevalence of CPD in postmenopausal women not taking
hormonal replacement is approximately 64.4%, whereas the
prevalence is 46.3% in postmenopausal women taking
hormonal replacement (11). Overall, 87% of the individuals
in our control group had CPD; this prevalence is compar-
able to that observed in Germany (10) and higher than that
observed in the U.S. (12). The association between breast
cancer treatment and oral health has not previously been
explored, but it is well known that ‘‘potentially complicat-
ing oral disease should be identified and corrected as early
as possible before commencement of anticancer therapy’’
(13). A comprehensive dental examination performed prior
to treatment can identify approximately 80% of the patients
with chronic odontogenic pathology who should receive
treatment to prevent local exacerbation or systemic spread
of ongoing infection while avoiding long-term oral compli-
cations, such as tooth loss (14).
On the other hand, the association between CPD and
cardiac morbidity is well established. Cardiac complications
have a serious impact on the life expectancy and quality of
life of breast cancer survivors. The risk for cardiac disease
may be increased in breast cancer survivors due to various
reasons other than CPD. Data from The Late Effects Breast
Cancer Cohort have revealed that 62.9 excess cases of
cardiovascular events per 10,000 patient-years are asso-
Table 1 - Medical parameters of breast cancer survivors.
Parameter N (%)
Tumor histology
Ductal 46 (95.8)
Lobular 2 (4.2)
Tumor stage
I 10 (20.8)
II 25 (52.1)
III 12 (25.0)
IV 1 (2.3)
Chemotherapy 33 (66.43)
Radiotherapy 41 (85.4)
Tamoxifen 40 (83.3)
Aromatase inhibitor 8 (16.7)
Surgery
Radical 18 (37.5)
Conservative 30 62.5)
Table 2 - Oral health parameters in breast cancer survivors
and controls.
Parameter Cases Controls p
Chronic periodontitis (%) 47 (98) 42 (87) NS
Total number of teeth 16 (3-28) 22 (4-30) 0.03
% of sites with detectable plaque 50 (0-100) 36.57 (0-100) NS
% of sites with gingival bleeding 16.05 (0-100) 0 (0-72) 0.04
% of sites with a depth $4 mm 3.3 (0.0-46.7) 3.6 (0.0-51.6) NS
Probing attachment level 2.8 (1.3-5.9) 3.1 (1.5-5.2) NS
Data are presented as the median (range).
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ciated with long-term breast cancer treatment and the main
risk factors are associated with radiotherapy of the internal
mammary chain, radiation with adjuvant chemotherapy
and smoking (15). After breast conservation treatment for
early stage disease, the subsequent development of cardiac
disease is more frequent in women with cancer of the left
breast (16). Anthracyclines, which are largely used in breast
cancer chemotherapy, have long been recognized as a cause
of cardiac dysfunctions, such as cardiomyopathy and heart
failure. These side effects are dose-dependent (17) and occur
more frequently in older patients (18). Trastuzumab, a
monoclonal antibody that blocks the HER-2 receptor and
improves the survival of women with HER-2-positive breast
cancer, is also associated with an increased risk of cardiac
dysfunction (19).
High-quality management of breast cancer patients should
include strategies for identifying patients who are at high risk
for cardiac disease and developing effective interventions to
prevent the development of late toxicities and minimize
their effects on quality of life (20). Epidemiological (7)
and experimental (5,21) evidence indicates that periodontal
disease is linked to an increased risk of cardiovascular
disease. Despite the limitations of our case-control design
and a lack of diversity in the therapeutic methods employed,
our data consistently revealed a high prevalence of period-
ontal disease and tooth loss after breast cancer treatment
in post-menopausal women. We believe that the current
evidence warrants the inclusion of a recommendation for a
comprehensive oral examination and treatment of identified
lesions in the breast cancer management protocols in the
public health system. Efforts have been made to screen for
and reduce or eliminate risk factors for cardiac disease,
such as smoking, elevated lipid levels and hypertension, in
patients who have breast cancer after menopause. However,
these efforts should also include the prevention and treat-
ment of oral diseases.
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